Labyrinth Therapeutics

Labyrinth Therapeutics is a biotechnology company focused on developing next-generation therapies for cancer and other serious diseases. Founded by a team of experienced industry veterans from companies like Bristol Myers Squibb and Celgene, the company leverages a proprietary platform to discover and develop novel therapeutic candidates. Labyrinth's primary focus is on targeted protein degradation and molecular glue therapies, aiming to address previously undruggable targets in oncology. The company is currently in the pre-clinical stage, advancing a pipeline of small molecule programs designed to provide transformative outcomes for patients with high unmet medical needs.